Guidance

Sickle cell and thalassaemia screening: prenatal diagnosis guidelines

This document explains the guidelines for referring prenatal diagnosis (PND) samples to molecular haemoglobinopathy laboratories.

From:
Public Health England
Published
1 May 2012

This publication was withdrawn on

Please refer to current guidelines for prenatal diagnosis in the Sickle cell and thalassaemia: screening handbook.

Documents

Guidelines for the referral of sickle cell and thalassaemia prenatal diagnosis samples to molecular haemoglobinopathy laboratories

PDF, 1.41 MB, 16 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This publication sets out the procedures for referring sickle cell and thalassaemia prenatal diagnosis samples to molecular haemoglobinopathy laboratories. This process is part of the sickle cell and thalassaemia (SCT) screening programme.

The document contains referral forms and sets out information about collecting outcome data.

Published 1 May 2012

Related content